PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
Clinical trial NCT03362060 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03362060
- Sponsor
- Massachusetts General Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-12
- Primary completion
- 2026-12-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.